Xiamen Humanity Hospital
Prostate cancer treatment cost in China runs from $11,500 to $24,000 for laparoscopic surgery, while advanced robotic da Vinci prostatectomy typically costs $18,800 to $27,800. Expenses depend on the cancer stage, chosen hospital tier, and specific technology used. International patients can expect 25% to 50% savings compared to the US. Top cities for high-end oncology care include Beijing and Guangzhou.
Typical Prostate Cancer Treatment Costs in China
Bookimed Expert Insight: Late-stage patients seeking alternatives to traditional chemotherapy find high value in specialized oncology centers. Fuda Cancer Hospital provides over 10 minimally invasive therapies, including NanoKnife and cryosurgery. Their clinical focus on advanced cases is well-suited for complex scenarios. For those requiring JCI-accredited multidisciplinary care, Yanda International Hospital offers Class A level III facilities. This ensures premium international protocols at approximately $22,000 to $25,800.
| China | Turkey | Austria | |
| Transurethral resection of the prostate (TURP) | from $7,500 | from $2,800 | from $5,500 |
| Tomotherapy | from $17,500 | from $12,000 | from $30,000 |
| Robotic da Vinci prostatectomy | from $18,800 | from $13,000 | from $20,000 |
| Radiotherapy for prostate cancer | from $14,500 | from $4,000 | from $14,000 |
| Proton-beam therapy | from $36,500 | from $70,000 | from $80,000 |
Professor Zheng Qiu Hong is Director of the Cell Therapy Research Center and a National Senior Expert in Biotherapy. He is a Professor and Master’s Supervisor at Fujian Medical University. He has more than 30 years of clinical experience in tumor molecular biology and biotherapy. From 2012 to 2013, he was a visiting scholar in stem cell research at the University of Connecticut School of Life Sciences. He previously held leadership roles at Fujian Cancer Hospital. These roles included Director of the Tumor Molecular Biology Laboratory and Director of the Surgical Oncology Research Laboratory. He also served as Deputy Director of the Fujian Key Laboratory of Tumor Biotherapy and Deputy Director of the Biotherapy and Immunotherapy Center.
Appointments include Standing Committee Member of the Biotherapy Committee of the Chinese Research Hospital Association. He is also a Committee Member of the Tumor Immunology and Biotherapy Committee of the Chinese Society for Immunology. In addition, he is Deputy Chair of the Academic Committee of the Xiamen Cell Therapy Research Center at the First Affiliated Hospital of Xiamen University.
Dr. Liu Shi Xin is the Vice Chairman of the Radiation Oncology Branch of the Chinese Medical Association. He serves as the Discipline Leader of the Oncology Center at Xiamen Humanity Hospital. Dr. Liu specializes in precision radiotherapy for thoracic and abdominal cancers. He is a recipient of the State Council Special Government Allowance for his medical contributions.
Professor Liang Xiaoxiao is the Department Director and Chief Physician in Neurorehabilitation. She holds a master’s degree in neurology. She is skilled in neuromodulation for disorders of consciousness, cognition, and movement. Her focus includes cases from cerebrovascular disease, Parkinson’s disease, and related conditions. She also performs ultrasound-guided botulinum toxin injections for blepharospasm, hemifacial spasm, limb spasticity, sialorrhea, and neuralgia.
Accreditations and roles: Member of the Neurorehabilitation, Cognitive Disorder Rehabilitation, and Craniocerebral Trauma Rehabilitation Committees of the Chinese Association of Rehabilitation Medicine. Standing Member of the Cognitive Disorder Rehabilitation Committee of the Fujian Association of Rehabilitation Medicine. Vice Chair of the Dementia and Cognitive Disorder Committee of the Xiamen Preventive Medicine Association. Vice President of the Parkinson’s Disease and Movement Disorders Committee of the Xiamen Medical Doctor Association. Standing Member of the Neuromodulation Committee of the Xiamen Medical Doctor Association. Recipient of the Most Beautiful Physician of Xiamen City (2024).
Dr. Lo Zhunchen brings over of medical expertise to prostate cancer care at Fuda Cancer Hospital.
Written by Anna Leonova
Written by Olena Sikoza
Top-rated hospitals for prostate cancer in China include JCI-accredited centers like Fuda Cancer Hospital and Yanda International Hospital. These facilities specialize in minimally invasive techniques and robotic surgery. Public academic giants in Beijing and Shanghai also lead in research and high surgical volumes.
Bookimed Expert Insight: While public hospitals handle massive volumes, JCI-accredited centers like Yanda International Hospital provide a unique bridge for international patients. Our data shows these facilities combine Western surgical protocols with traditional Chinese approaches. This integration is particularly useful for managing treatment side effects. Yanda also holds the Class A Level III designation. This is the highest medical ranking achievable in the Chinese healthcare system.
Patient Consensus: Patients note that major city hospitals offer robotic systems which improve recovery. Many suggest hiring a translator as English support can be limited during follow-up Care.
China offers advanced prostate cancer care through robotic systems and specialized particle radiation therapies. Facilities utilize 5G-enabled telesurgery and Carbon Ion Radiotherapy to treat complex cases. These technologies reach high-risk tumors with precise energy while protecting surrounding healthy tissue and critical urinary functions.
Bookimed Expert Insight: Patient data shows a shift toward specialized non-surgical centers like Fuda Cancer Hospital in Guangzhou. This facility has treated over 30,000 international patients using 10+ types of minimally invasive therapies. Their focus on microwave hyperthermia and vascular intervention offers alternatives for those seeking to avoid traditional chemotherapy.
Patient Consensus: Patients value the availability of the NanoKnife system for its ability to treat tumors near sensitive nerves. Many note that the high volume of international cases at JCI-accredited hospitals makes the coordination of complex radiation schedules much smoother.
Metastatic prostate cancer management in China centers on aggressive multimodal protocols combining androgen deprivation therapy with specialized minimally invasive techniques. Advanced centers utilize cryosurgery, NanoKnife, and vascular interventional therapy. These approaches complement international standards like hormonal manipulation and chemotherapy for late-stage cases.
Bookimed Expert Insight: China's top oncology centers like Fuda Cancer Hospital and Yanda International Hospital stand out by treating approximately 2,500,000 patients annually with 30,000+ international cases. Data shows these JCI-accredited facilities often prioritize organ-sparing technologies over radical surgery for metastatic patients. Patients seeking care in Beijing or Guangzhou can access specialists like Dr. Lo Zhunchen, who has over 20 years of experience in complex hematology and oncology protocols.
Patient Consensus: Patients note that top-tier hospitals provide faster access to advanced PSMA-targeted therapies and clinical trials compared to Western countries. It is important to confirm genomic testing for BRCA mutations before starting combination treatments to ensure the most effective therapy plan.
Traditional Chinese Medicine (TCM) serves as a complementary therapy for prostate cancer in China. It improves survival rates and manages treatment side effects alongside conventional care. Specific formulations like Xihuang Pills reduce chemotherapy-induced pain. TCM also helps inhibit tumor progression and may reduce bone metastasis risk.
Bookimed Expert Insight: While many search for TCM as a primary cure, China’s high-volume Class A Level III hospitals like Yanda International Hospital focus on a hybrid model. They integrate 28,500 modern technologies with traditional approaches. This suggests the most effective path is using TCM specifically for recovery and symptom control, rather than replacing standard oncology protocols. Combining international surgical standards with local herbal recovery may explain why these centers successfully manage 2,500,000 patients annually.
Patient Consensus: Patients note that TCM is most effective for relieving urinary issues and boosting energy after surgery or radiation. Many emphasize the importance of consulting a Western oncologist first, as certain herbs can cause unexpected PSA spikes or interfere with hormone medications.
Chinese hospitals are identified as top-tier based on Class A Level III national grading and JCI (Joint Commission International) accreditation. These centres must provide robotics, such as the Da Vinci system, and multidisciplinary care. High clinical volume and specialists with over 20 years of experience are essential markers.
Bookimed Expert Insight: Patient volume is the most reliable quality signal in China. Larger institutions like Yanda International Hospital treat 2,500,000 patients annually. This scale leads to specialised urology departments with high monthly case numbers.
Patient Consensus: Patients prioritise surgical teams with high case volumes over facility aesthetics. They frequently look for integrated centres where urology, oncology, and pathology teams work together. This helps ensure accurate staging and coordinated care in China.
Major Chinese cancer centres use multi-disciplinary teams (MDTs) to manage prostate cancer care. These teams integrate urology, radiation oncology, and chemotherapy into single treatment plans. Top-tier Class A level III hospitals follow national CSCO guidelines to coordinate complex cases.
Bookimed Expert Insight: Many think of China for traditional medicine. However, the MDT model there is deeply integrated with heavy infrastructure. Class A level III hospitals like Yanda International operate massive campuses. These include 39 departments and 3,000 beds. This scale helps prostate cancer patients access nuclear medicine and robotic surgery. They can also access interventional therapy in one location without transferring between facilities.
China uses precision tools like PSMA PET/CT imaging and multiparametric MRI for prostate cancer diagnosis. Treatment options include robotic-assisted surgery, NanoKnife ablation, and carbon ion radiotherapy. Chinese JCI-accredited facilities offer these therapies for localised and metastatic cases.
Bookimed Expert Insight: Many global centres focus on standard chemotherapy. However, leading Chinese facilities like Fuda Cancer Hospital specialise in over 10 minimally invasive alternatives. Their expertise in regional hyperthermia and vascular interventional therapy provides options for patients. These options help those who cannot tolerate traditional systemic treatments. This focus on local-regional control is valuable for late-stage cases where preserving organ function is a priority.